Search Results

All assets of the regenerative medicine and cell therapy company are being divested to its research partner to the tune of $2 million in the form of a credit bid.

Athersys, Inc. announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K.

Evoke Pharma, Inc. announced that its flagship product, GIMOTI has been nominated for Healio’s Annual Disruptive Innovators Awards under the Healio Industry Breakthrough Award category.

Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, announced that Meg Heim has been appointed to the company’s Board of Directors.

Athersys, Inc. announced that its partner, HEALIOS K.K., has provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.

Athersys, Inc. announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem ® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365.

Athersys, Inc. announced that its partner, HEALIOS K.K., has reported topline results for its Japan ischemic stroke study, TREASURE.

Medical publisher Healio, announces the launch of the new publication, Healio Psoriatic Disease

Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® (invimestrocel) cell therapy treatment in patients who have suffered an ischemic stroke.

Healio is pleased to announce PM360 has named Healio.com as one of the most innovative services of 2020. The all-new Healio was selected as part of PM360’s 9 th Annual Innovations Issue, recognizing the year’s most innovative services, compan